Previous 10 | Next 10 |
WAKEFIELD, MA / ACCESSWIRE / October 25, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline results the week of November 8 th from its Phase 2 clinical trial of Brilacidin for ...
WAKEFIELD, MA / ACCESSWIRE / September 23, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treat...
WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information regarding the status of its randomized, double-blind, placebo-controlled Phase 2 clini...
WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Company’s defensin-mimetic drug candidate b...
Brilacidin showed potent inhibition in multiple human cell lines and in different strains of alphaviruses and bunyaviruses, building on earlier antiviral work in coronaviruses These data collectively support Brilacidin’s broad-spectrum antiviral potential, leveraging Brilacidin...
loops7/E+ via Getty Images Innovation Pharmaceuticals ([[IPIX]] +3.2%) announced that antiviral research related to Brilacidin was accepted for an Oral Presentation at the 2021 Military Health System Research Symposium ((MHSRS)). The presentation among 20% accepted out of nearly 2,300 su...
Presentation to be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Companyȁ...
WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 cli...
Innovation Pharmaceuticals ([[IPIX]] -1.3%) announces that enrollment in the company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent.The company said that it anticipates full enrollment to be completed in about two weeks.Innovation is develo...
WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-1...
News, Short Squeeze, Breakout and More Instantly...
Innovation Pharmaceuticals Inc Company Name:
IPIX Stock Symbol:
OTCMKTS Market:
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to provide shareho...
WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States Patent and Trade Office (USPTO), on June 6, 2023, granted a patent, &...
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to inform sh...